Revenue missed sharply, while pipeline progress and cash runway held steady

The quarter missed the limited published financial bar. Q2 revenue was $1.4 million versus a published consensus of roughly $12.6 million, while EPS was $(0.09) versus an expected $(0.08), making the headline result worse than anticipated. The revenue gap is largely timing-related: prior Bristol Myers Squibb obligations were completed in 2025 and the Astellas collaboration wound down during Q2, rather than reflecting a new commercial deterioration.

The clinical update is progress, not a de-risking event. Varseta-M enrollment is complete at 113 patients, new expansion cohorts are starting in three additional gastrointestinal cancers, and the company still targets a late-2026 data update and a first registrational study in the first half of 2027. But the filing provides no efficacy data, no dose-selection result, and no change to those previously expected milestones; the near-term investment case remains dependent on future clinical readouts (Pipeline Program Updates — Varseta-M).

The balance sheet is the main offset to the earnings miss. CytomX reported a projected cash runway through at least the second half of 2028, and the $37.0 million Regeneron target-selection payment received in July is not included in the June 30 cash figure. That payment and the broader Regeneron expansion were already announced before this filing, so they improve funding visibility more than they add fresh surprise today (Corporate and Financial; Condensed Balance Sheets).

Net: modestly worse than expected financially, with no new clinical catalyst to reverse the read. Higher R&D spending reflects manufacturing and development activity for Varseta-M, while the collaboration-driven revenue decline is explainable; nevertheless, the actual quarter missed consensus and the filing mainly reaffirmed an already-known pipeline and partnership setup rather than delivering new evidence of clinical success.